NAMA
PACB icon

Nikko Asset Management Americas’s Pacific Biosciences PACB Stock Holding History

Nikko Asset Management Americas’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Sell
6,009,715
-1,028,272
-15% -$1.5M 0.13% 92
2026
Q1 		$9.22M Sell
7,037,987
-770,593
-10% -$1.38M 0.13% 86
2025
Q4 		$14.6M Sell
7,808,580
-868,978
-10% -$1.67M 0.17% 82
2025
Q3 		$11M Sell
8,677,558
-540,897
-6% -$732K 0.11% 91
2025
Q2 		$11.3M Sell
9,218,455
-346,876
-4% -$401K 0.11% 87
2025
Q1 		$11.2M Sell
9,565,331
-613,170
-6% -$941K 0.14% 82
2024
Q4 		$18.4M Sell
10,178,501
-1,687,265
-14% -$3.29M 0.2% 72
2024
Q3 		$20.1M Sell
11,865,766
-774,795
-6% -$1.27M 0.23% 67
2024
Q2 		$17.2M Sell
12,640,561
-183,824
-1% -$371K 0.2% 71
2024
Q1 		$48M Sell
12,824,385
-375,990
-3% -$2.2M 0.48% 49
2023
Q4 		$130M Sell
13,200,375
-247,291
-2% -$2.02M 1.25% 22
2023
Q3 		$112M Sell
13,447,666
-202,282
-1% -$2.31M 1.34% 21
2023
Q2 		$181M Sell
13,649,948
-356,567
-3% -$4.33M 1.91% 16
2023
Q1 		$159M Sell
14,006,515
-159,678
-1% -$1.59M 1.84% 18
2022
Q4 		$116M Sell
14,166,193
-225,769
-2% -$1.95M 1.67% 19
2022
Q3 		$84.5M Buy
14,391,962
+46,477
+0.3% +$267K 1.08% 24
2022
Q2 		$61M Buy
14,345,485
+324,280
+2% +$1.97M 0.75% 30
2022
Q1 		$128M Buy
14,021,205
+2,106,180
+18% +$24.2M 0.94% 25
2021
Q4 		$245M Buy
11,915,025
+2,567,023
+27% +$61.9M 1.29% 24
2021
Q3 		$236M Buy
9,348,002
+1,225,930
+15% +$36.3M 1.01% 28
2021
Q2 		$284M Buy
8,122,072
+2,874,835
+55% +$83.6M 1.11% 30
2021
Q1 		$175M Buy
5,247,237
+228,099
+5% +$7.98M 0.86% 38
2020
Q4 		$130M Buy
5,019,138
+902,585
+22% +$15.3M 0.74% 45
2020
Q3 		$41.2M Buy
+4,116,553
New +$23.7M 0.37% 59
2018
Q4 		– Sell
-6,478
Closed -$36K – 150
2018
Q3 		$36K Buy
+6,478
New +$27.8K ﹤0.01% 140

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nikko Asset Management Americas's PACB Position: Q2 2026 in Review

Nikko Asset Management Americas reduced its Pacific Biosciences (PACB) stake by 15% in Q2 2026, selling an estimated $1.5M and leaving 6,009,715 shares worth $10M. The position accounts for 0.13% of the portfolio, ranked #92.

Nikko Asset Management Americas first reported a position in PACB in Q3 2018 and has held it in 25 quarters since. The position peaked at $284M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Nikko Asset Management Americas held 6,009,715 shares of Pacific Biosciences worth $10M as of Q2 2026.
  • Nikko Asset Management Americas sold 1,028,272 Pacific Biosciences shares in Q2 2026, an estimated $1.5M.
  • Pacific Biosciences made up 0.13% of Nikko Asset Management Americas's portfolio in Q2 2026, its #92 holding.
  • Nikko Asset Management Americas first reported a position in Pacific Biosciences in Q3 2018 and has held it in 25 quarters since.
  • Nikko Asset Management Americas's Pacific Biosciences position peaked at $284M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.